RxDoctor Payments Data

Sohail Abdul Salim, MD

Nephrology · Phoenix, AZNPI 1457658007

Payments from drug & device makers

$1,092in general payments, 2019–2025

Across 30 payments — averaging $36.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$323
  • Amgen$317
  • Vantive US Healthcare LLC$128
  • Baxter Healthcare$124
  • Otsuka America Pharmaceutical, Inc.$73
  • Akebia Therapeutics Inc$41
  • plus $86 from 5 others

What the payments were for

  • Food & beverage$1,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,092 in reported general payments places this provider in the 30th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$182,531
Medicare patients
331
Services billed
1,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProcritEpoetin Alfa23$54,101
EpogenEpoetin Alfa35$53,287
LokelmaSodium Zirconium Cyclosilicate64$35,282
Albuked-25Albumin Human20$27,247
FarxigaDapagliflozin Propanediol35$19,917
FosrenolLanthanum Carbonate37$19,337
RetacritEpoetin Alfa-Epbx24$17,519
Sevelamer Carbonate28$17,338
Calcium Acetate16$1,514
Sodium Chloride0.9 % Sodium Chloride11$496
Doxercalciferol22$347
Losartan Potassium36$281
Furosemide27$186
Nifedipine ErNifedipine18$182
Lisinopril14$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$323$55,19999 claims
AmgenEpogen$317$53,28735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 259 nephrology providers in Arizona.

Other nephrology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →